Why Aren't Medical Guidelines on Vitamin D Designed to Prevent Most Diseases?

By Wayne Persky

RSS Feed

Official medical guidelines often contain worrisome problems. One of those, for example, is the disparity between minimal vitamin D threshold levels set by official guidelines, and the levels that epidemiological data suggest are optimal for much broader disease prevention. This disconnect is real and has been the subject of growing debate among researchers, clinicians, and patient advocates. Does this risky gap exists because of unintended oversight, or a more systemic incentive problem.

Official medical vitamin D guidelines reflect minimal standards.

At the core of the problem is the fact that the medical guidelines list minimal thresholds that are designed to prevent acute deficiency disease — not to optimize health. For example, medical guidelines from the Institute of Medicine or Endocrine Society define deficiency in terms of preventing:
​

• Rickets in children
• Osteomalacia in Adults
• Severe Hypocalcemia

These guidelines typically set the sufficiency cutoff around 20–30 ng/mL (50–75 nmol/L). But these levels are based on outdated endpoints and ignore the non-skeletal roles of vitamin D, such as:

• Immune system function
• Autoimmune disease risk reduction
• Cancer prevention
• Mental health regulation

By contrast, epidemiological studies routinely associate 40–60 ng/mL (100–150 nmol/L) with lower risks of:

• IBD and other autoimmune diseases
  
• Certain cancers (especially colorectal)
  
• Respiratory infections
  
• Cognitive decline
  
• All-cause mortality

Fear of toxicity has led to overly conservative guidelines.

• Vitamin D is fat-soluble, meaning it can accumulate in tissues
  
• Excess vitamin D can lead to hypercalcemia, though this is rare, and typically requires sustained levels greater than 150 ng/mL (375 mmol.L), plus high calcium intake, and often, a magnesium deficiency.

​However, numerous studies show that levels up to 100 ng/mL are safe and that daily supplementation of 2000–5000 IU is rarely associated with harm, especially when magnesium and vitamin K2 intake are adequate. Yet, the official upper intake limit remains at 4000 IU/day, a conservative figure not supported by more recent safety data.

Guideline selecting committees reflect medical conservatism and risk aversion.

Organizations such as the Endocrine Society tend to prioritize:
​

• Large randomized controlled trials (RCTs) over observational data
• Clear cause-effect relationships
• Prevention of "over-testing" or "over-supplementation" rather than maximizing wellness

This conservative approach leads to an unrealistic "wait for perfect proof" mentality, despite real-world, population-level correlations suggesting otherwise.

Pharmaceutical and insurance incentives tend to disincentive prevention.

While it may be unfair to claim the system is intentionally keeping people deficient to drive healthcare profits, structural incentives do create passive disincentives for prevention:
​

• There's no profit in preventing a disease that doesn’t require long-term pharmaceutical treatment
• Vitamin D is cheap, non-patentable, and widely available without prescription
• Testing and supplementing for prevention are not reimbursed by most insurance plans
• Hospitals and drug companies benefit more from managing chronic diseases than preventing them

In this sense, the system, as designed, doesn’t reward optimal public health outcomes—it rewards sick care.

Guidelines recommend inadequate testing and diagnostic practices.

Routine vitamin D testing is discouraged for the general population under current guidelines, despite:
​

• The high prevalence of deficiency or insufficiency (42% overall, >80% in Black Americans)
• The low cost of blood testing
• The safety and affordability of treatment

​Note that this is similar to the neglect seen with magnesium testing, where reliance on inaccurate serum levels prevents effective diagnosis and intervention.

The message sent to the public is confusing and contradictory.

Medical authorities often:

• Warn against sun exposure (the main source of vitamin D, as designed by our evolution)
• Discourage supplement use unless there’s a known deficiency
• Downplay observational findings due to fear of “false hope” or industry influence

​This has led to public confusion, under-supplementation, and persistent population-level deficiency—despite decades of emerging research.

So do the guidelines encourage sickness rather than disease prevention?

There's no clear evidence of any coordinated conspiracy, of course, but:

• Systemic inertia
• Profit-driven care models
• Bureaucratic risk aversion
• Lack of accountability for poor preventive outcomes

all contribute to the persistence of low thresholds that serve institutional interests more than patient well-being. In that light, it's fair to argue the system is not designed to promote optimal health. It manages disease reactively rather than preventing it proactively.

Vitamin D levels are especially important for IBD patients.

Research shows that vitamin D deficiency affects up to 100% of Crohn's disease patients and 45% of those with ulcerative colitis (Johnson, 2025, May 20).1 The deficiency is not merely a result of disease activity — it likely contributes to its onset. Mechanistically, low vitamin D leads to:
​

• Upregulated gut inflammation
• Microbial imbalance (dysbiosis)
• Mucosal barrier breakdown

Low vitamin D correlates with increased disease activity, more frequent surgeries, higher relapse rates, and poor treatment responses. A 2023 Cochrane review even found reduced relapse rates in patients supplementing with vitamin D, although evidence quality limited definitive conclusions.

Another study followed 5,474 IBD patients for 13 years and found that those with adequate vitamin D levels had significantly reduced bowel resection risks — by 34% in IBD overall and 46% in ulcerative colitis (Dan et al., 2024).2​

The takeaway:

Despite self-serving and often confusing official vitamin D guidelines:

• Targeting 50–60 ng/mL (125–150 mmol/L) is evidence-based, and safe for most people
• This level offers protection against a wide range of diseases beyond rickets and osteomalacia
• Testing and supplementing are low-cost, low-risk, and high-reward
• And a vitamin D level of 50–60 ng/mL (125–150 mmol/L) is highly beneficial for most IBD and other autoimmune disease patients)​

Additional evidence of the safety of higher doses:

The Calgary vitamin D study

was a three year, double-blind, random controlled study (RCT) involving adults aged 55–70, and compared daily doses of either 4000 IU or 10,000 IU of vitamin D (Burt et al., 2019).3 The findings showed that both 4000 and 10,000 IU per day were well-tolerated. Bone density was generally unaffected, but was slightly decreased at the highest does, suggest the safety, but no skeletal benefit at high levels in already sufficient adults.

The VIDAMS study (multiple sclerosis)

compared 5000 IU per day versus 600 IU per day in relapsing remitting multiple sclerosis patients (Cassard et al., 2023).4 The findings showed that the higher dose yielded fewer active MRI lesions, indicating potential benefit beyond bone health.​

A systematic review and meta-analysis:

based on 32 reviews of clinical trials involving 8400 children who received high-dose vitamin D treatments ranging from 1200 to 10,000 IU per day, and bolus doses ranging from 30,000 IU per week to a single dose of 600,000 IU, found that no increased risk of serious adverse events was associated with high-dose vitamin D treatments (Brustad et al., 2022).5​

References:

1. Johnson, D. A. (2025, May 20). The Overlooked Link Between Vitamin D and GI Health. Medscape, Retrieved from https://www.medscape.com/viewarticle/overlooked-link-between-vitamin-d-and-gi-health-2025a1000bki

2. Dan, L., Wang, S., Chen, X., Sun, Y. Fu, T., Deng, M., . . . Wang, X. (2024). Circulating 25-hydroxyvitamin D concentration can predict bowel resection risk among individuals with inflammatory bowel disease in a longitudinal cohort with 13 years of follow-up. International Journal of Surgery, [Published online]. Retrieved from https://journals.lww.com/international-journal-of-surgery/abstract/9900/circulating_25_hydroxyvitamin_d_concentration_can.1249.aspx

3. Burt, L. A., Billington, E. O., Rose, M. S., Raymond, D. A., Hanley, D. A., and Boyd, S. K. (2019). Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial. JAMA, 322(8), pp 736–745, Retrieved from https://pubmed.ncbi.nlm.nih.gov/31454046/

4. Cassard, S. D., Fitzgerald, K. C., Qian, P., Emrich, S. A., Azevedo, C. J., Goodman, A.D., . . . Mowry, E. M. (2023) High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial. EClinicalMedicine, 13;59,101957. Retrieved from https://pubmed.ncbi.nlm.nih.gov/37125397/

5. Brustad, N., Yousef, S., Stokholm, J., Bønnelykke, K., Bisgaard, H., and Chawes, B. L. (2022). Safety of High-Dose Vitamin D Supplementation Among Children Aged 0 to 6 Years: A Systematic Review and Meta-analysis. JAMA Network Open, 5(4). e227410 Retrieved from https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2791031